Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Rilonacept (Primary)
- Indications Systemic scleroderma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
Most Recent Events
- 01 Dec 2017 Status changed from recruiting to completed.
- 29 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017.
- 10 Apr 2015 New trial record